Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18932666 | 0.92 | HTR2A (0.48) | CNR2HTR2AMAPTSLC6A3OPRM1 | |
| SCHEMBL18919132 | 0.90 | CNR2 (0.50) | CNR2HTR2AAVPR1ACNR1SIGMAR1 | |
| SCHEMBL18919106 | 0.90 | CNR2 (0.49) | CNR2HTR2AAVPR1ACNR1SIGMAR1 | |
| SCHEMBL18919072 | 0.89 | KMT2A (0.49) | HTR2ASIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18919199 | 0.88 | CNR2 (0.54) | CNR2CNR1SIGMAR1 | |
| SCHEMBL17444528 | 0.85 | CNR2 (0.67) | CNR2CNR1 | |
| SCHEMBL17444690 | 0.85 | CNR2 (0.59) | CNR2HTR2ACNR1 | |
| SCHEMBL18919035 | 0.84 | CNR2 (0.43) | CNR2HTR2AMAPTSLC6A3OPRM1 | |
| SCHEMBL18919036 | 0.84 | CNR2 (0.43) | CNR2HTR2AMAPTSLC6A3OPRM1 | |
| SCHEMBL16739343 | 0.84 | TSHR (0.48) | CNR2MAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-08 | — | — | US | disclosed |
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-08 | — | — | US | disclosed |
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | CNR2 2724/4885HTR2A 1880/4885AVPR1A 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.